1. Bilchenko A.V. Hyperuricemia as a risk factor of cardiovaskular morbidity and mortality.// Health of Ukraine, Theme No. 2009, June, p. 46-48. (in Russian)
2. Britov A.N., Eliseev N.A., Deev A.D. et all. Relationship between hypertension, metabolic desorders and urate nephropathy.// Therapeutic Archives, 2006, 5: 41–45. (in Russian)
3. Diagnosis and treatment of metabolic syndrome. Russian recommendations. Moscow, 2007. Cardiovaskular Therapy and Prevention, 2007; app. 2:3-26. (in Russian)
4. Lebedeva M.V., Balkarov I.M., Shovskaya T.N. Urate nephropathy - a cause of reversible Renal failure in a young adult patient. // Therapeutic Archives, 2006, 5: 69–71. (in Russian)
5. Olbinskaya L.I., Hapaeva B.A. Blood pressure monitoring in diagnostic and treatment of hypertension.// Guidance for doctors and senior students, Moscow, 1997, 35 p. (in Russian)
6. Samorodskaya I.V. Cardiovascular morbidity and cardiovascular events risk factors in the Russian Federation.// Cardiovaskular Therapy and Prevention, 2005, №4, part II. - p. 94-100. (in Russian)
7. Hoieggen A., Alderman M.N., Kjeldsen S.E. et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study // Kidney Int. 2004. 65. 1041–1049.
8. Kjeldsen S.E., Julius S., Mancia G et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high–risk hypertensive patients: the VALUE trial // J. Hypertens. 2006. 24. 1405–1412.
9. Mancia G., De Backer G., Dominiczak A. et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension(ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J. 2007. 28. 1462–1536.
10. Matthews D.R., Hosker J.P., Rudenski A.S. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. 1985. 28. 412–419.
11. Reappraisal of European guidelines on hypertension management: a ESH Task Force document 2009 // J. Hypertens. 2009. 27. 2121–2158.
12. Rho Y.H., Choi S.J., Lee Y.H. et al. The prevalence of metabolic syndrome in patients with gout: A multicenter study // J. Korean Med. Sci. 2005. 20. 1029–1033.
13. Top C., Cingozbay B.Y., Terekeci H. et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension // J. Int. Med. Res. 2002. 30. 15– 20.
14. Weycker D., Edelsberg J., Vincze G. et al. Risk of diabetes in a real–world setting among patients initiating antihypertensive therapy with valsartan or amlodipine // J. Hum. Hypertens. 2007. 21. 374–380.